The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited.

For further information call: 800-211-2769

The Medical Letter® On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication

Volume 50 (Issue 1297) October 20, 2008 www.medicalletter.org

IN BRIEF

Melamine

Melamine present in infant formula and other milk products has been associated with widespread illness and some deaths among infants in China. It was also identified in pet food sold in North America after a large number of pets became ill and some died. In both the infants and the pets, renal injury appeared to be the cause.¹

Melamine $(C_3H_6N_6)$ is a heterocyclic compound, two-thirds nitrogen by weight, that is slightly soluble in water. When combined with formaldehyde, it forms melamine resin, which has a wide variety of industrial applications including the manufacturing of kitchenware, whiteboards and laminate flooring. Because of its nitrogen content, melamine has been illegally added to products such as milk, wheat gluten and rice protein to factitiously boost the apparent protein content; common assays for protein content do not distinguish between amino-acid nitrogen and non-protein nitrogen.

Melamine itself is relatively nontoxic; the FDA has established, based on an extrapolation from studies in rats, a tolerable daily intake of 0.63 mg/kg/day.¹ However, the combination of melamine with cyanuric acid (a water disinfectant and/or impurity associated with melamine production that itself is also nontoxic) results in the formation of insoluble crystals that precipitate in renal tubules following ingestion and may cause acute renal failure.²-⁴ Infants may be especially sensitive to this mechanism of toxicity.

Treatment of humans or animals poisoned with these compounds is largely supportive. Hemodialysis may be indicated, depending on the degree of renal failure. Whether hemodialysis removes melamine or related compounds is unknown.

 U.S. Food and Drug Administration. Interim safety and risk accessment of melamine and its analogues in food for humans. October 3, 2008. Available at www.cfsan.fda. gov/~dms/melamra3.html. Accessed October 14, 2008.

- CA Brown et al. Outbreaks of renal failure associated with melamine and cyanuric acid in dogs and cats in 2004 and 2007. J Vet Diagn Invest 2007;19:525.
- RL Dobson et al. Identification and characterization of toxicity of contaminants in pet food leading to an outbreak of renal toxicity in cats and dogs. Toxicol Sci 2008; 106:251.
- World Health Organization. Melamine and cyanuric acid: toxicity, preliminary risk assessment and guidance on levels in food. September 25, 2008. Available at www.who.int/foodsafety/fs_management/Melamine.pdf. Accessed October 14, 2008.

The Medical Letter®

EDITOR IN CHIEF: Mark Abramowicz. M.D.

EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., Weill Medical College

of Cornell University

EDITOR: Jean-Marie Pflomm, Pharm.D.

ASSISTANT EDITORS, DRUG INFORMATION:

Susan M. Daron, Pharm.D. Blaine M. Houst, Pharm.D.

Corinne E. Zanone. Pharm.D. CONTRIBUTING EDITORS:

Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School Eric J. Epstein, M.D. Albert Einstein College of Medicine

CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,

Pharm.D., University of Washington ADVISORY BOARD:

Jules Hirsch, M.D., Rockefeller University

David N. Juurlink, BPhm, M.D., PhD, Sunnybrook Health Sciences Centre

Richard B. Kim, M.D., University of Western Ontario

Gerald L. Mandell, M.D., University of Virginia School of Medicine

Hans Meinertz, M.D., University Hospital, Copenhagen

Dan M. Roden, M.D., Vanderbilt University School of Medicine

F. Estelle R. Simons, M.D., University of Manitoba

Neal H. Steigbigel, M.D., New York University School of Medicine SENIOR ASSOCIATE EDITORS: Donna Goodstein, Amy Faucard

ASSOCIATE EDITOR: Cynthia Macapagal Covey

EDITORIAL FELLOW: Lauren K. Schwartz, M.D., Mount Sinai School of Medicine

DRUG INTERACTIONS FELLOW: Manouchkathe Cassagnol, Pharm.D., St. John's University

PRODUCTION COORDINATOR: Chervl Brown ASSISTANT MANAGING EDITOR: Liz Donohue

MANAGING EDITOR: Susie Wong

EXECUTIVE DIRECTOR OF SALES: Gene Carbona FULFILLMENT & SYSTEMS MANAGER: Cristine Romatowski **DIRECTOR OF MARKETING & COMMUNICATIONS: Joanne F. Valentino**

VP FINANCE & OPERATIONS: Yosef Wissner-Levy

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants or donations. The content of The Medical Letter is controlled by the Editor, who declares no conflict. The members of the Advisory Board are required to disclose any potential conflict of interest.

No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy or omission.

Subscription Services

Mailing Address:

The Medical Letter, Inc. 1000 Main Street

New Rochelle, NY 10801-7537

Customer Service:

Call: 800-211-2769 or 914-235-0500

Fax: 914-632-1733

Web Site: www.medicalletter.org E-mail: custserv@medicalletter.org

To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org

Subscriptions (US):

1 year - \$98; 2 years - \$167; 3 years - \$235. \$49 per year for students, interns, residents and fellows in the US and Canada. CME: \$49 for 26 credits.

E-mail site license inquiries to: info@medicalletter.org or call

800-211-2769 x315. Special fees for bulk subscriptions.

Special classroom rates are available. Back issues are \$12 each. Major credit

Copyright 2008. ISSN 1523-2859